Ema Ozaki

1.7k total citations · 1 hit paper
23 papers, 1.3k citations indexed

About

Ema Ozaki is a scholar working on Ophthalmology, Molecular Biology and Neurology. According to data from OpenAlex, Ema Ozaki has authored 23 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Ophthalmology, 11 papers in Molecular Biology and 6 papers in Neurology. Recurrent topics in Ema Ozaki's work include Retinal Diseases and Treatments (12 papers), Retinal Development and Disorders (5 papers) and Ocular Diseases and Behçet’s Syndrome (5 papers). Ema Ozaki is often cited by papers focused on Retinal Diseases and Treatments (12 papers), Retinal Development and Disorders (5 papers) and Ocular Diseases and Behçet’s Syndrome (5 papers). Ema Ozaki collaborates with scholars based in Ireland, United States and United Kingdom. Ema Ozaki's co-authors include Sarah Doyle, Matthew Campbell, Marian M. Humphries, Peter Humphries, Anna‐Sophia Kiang, Paul F. Kenna, Ed C. Lavelle, G. Jane Farrar, Robert G. Salomon and Andrés Mori and has published in prestigious journals such as Nature Medicine, Nature Communications and The Journal of Immunology.

In The Last Decade

Ema Ozaki

23 papers receiving 1.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives

2015 343 citations Sarah Doyle, Ema Ozaki et al. Journal of Inflammation Research profile →

Peers

Countries citing papers authored by Ema Ozaki

Since Specialization

Citations

This map shows the geographic impact of Ema Ozaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ema Ozaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ema Ozaki more than expected).

Fields of papers citing papers by Ema Ozaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ema Ozaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ema Ozaki. The network helps show where Ema Ozaki may publish in the future.

Co-authorship network of co-authors of Ema Ozaki

This figure shows the co-authorship network connecting the top 25 collaborators of Ema Ozaki. A scholar is included among the top collaborators of Ema Ozaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ema Ozaki. Ema Ozaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Title	Journal	Authors	Indexed citations
1	Endothelial IL-36 receptor activation promotes vascular stability to limit pathological microvessel permeability in the CNS	Cell Reports	Graeme P. Sullivan, Kevin P. Byrne et al.	1
2	Multiomic Mass Spectrometry Imaging to Advance Future Pathological Understanding of Ocular Disease	Metabolites	Ema Ozaki, Susan G. Campbell et al.	4
3	SARM1 Promotes Photoreceptor Degeneration in an Oxidative Stress Model of Retinal Degeneration	Frontiers in Neuroscience	Ema Ozaki, Chris Greene et al.	5
4	Minocycline suppresses disease-associated microglia (DAM) in a model of photoreceptor cell degeneration	Experimental Eye Research	Ema Ozaki, Conor P. Delaney et al.	25
5	SARM1 deficiency promotes rod and cone photoreceptor cell survival in a model of retinal degeneration	Life Science Alliance	Ema Ozaki, Nuno Neto et al.	34
6	Toll-like Receptor 2 Facilitates Oxidative Damage-Induced Retinal Degeneration	Cell Reports	Kelly Mulfaul, Ema Ozaki et al.	45
7	Advanced late-onset retinitis pigmentosa with dominant-acting D477G RPE65 mutation is responsive to oral synthetic retinoid therapy	BMJ Open Ophthalmology	Paul F. Kenna, Marian M. Humphries et al.	11
8	IL-33 deficiency causes persistent inflammation and severe neurodegeneration in retinal detachment	Journal of Neuroinflammation	Josy Augustine, Sofia Pavlou et al.	38
9	Dysregulated claudin-5 cycling in the inner retina causes retinal pigment epithelial cell atrophy	JCI Insight	Natalie Hudson, A. Hopkins et al.	50
10	Type 1 IFN Induction by Cytosolic Nucleic Acid Is Intact in Neonatal Mononuclear Cells, Contrasting Starkly with Neonatal Hyporesponsiveness to TLR Ligation Due to Independence from Endosome-Mediated IRF3 Activation	The Journal of Immunology	Kiva Brennan, Eamon P. Breen et al.	11
11	Interleukin‐33 regulates tissue remodelling and inhibits angiogenesis in the eye	The Journal of Pathology	Sofia Theodoropoulou, David A. Copland et al.	50
12	Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives breakdown →	Journal of Inflammation Research	Sarah Doyle, Ema Ozaki et al.	343
13	IL-18 Immunotherapy for Neovascular AMD: Tolerability and Efficacy in Nonhuman Primates	Investigative Ophthalmology & Visual Science	Sarah Doyle, Francisco J. López et al.	33
14	An Overview of the Involvement of Interleukin-18 in Degenerative Retinopathies	Advances in experimental medicine and biology	Matthew Campbell, Sarah Doyle et al.	7
15	Inflammation in Age-Related Macular Degeneration	Advances in experimental medicine and biology	Ema Ozaki, Matthew Campbell et al.	37
16	Plasmonics-enhanced and optically modulated delivery of gold nanostars into brain tumor	Nanoscale	Hsiangkuo Yuan, Christy Wilson et al.	47
17	Targeted suppression of claudin-5 decreases cerebral oedema and improves cognitive outcome following traumatic brain injury	Nature Communications	Matthew Campbell, Finnian Hanrahan et al.	91
18	NLRP3 has a protective role in age-related macular degeneration through the induction of IL-18 by drusen components	Nature Medicine	Sarah Doyle, Matthew Campbell et al.	348
19	Systemic low‐molecular weight drug delivery to pre‐selected neuronal regions	EMBO Molecular Medicine	Matthew Campbell, Marian M. Humphries et al.	31
20	Systemic delivery of therapeutics to neuronal tissues: a barrier modulation approach	Expert Opinion on Drug Delivery	Matthew Campbell, Ema Ozaki et al.	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact